OOIR: Observatory of International Research

Papers

(The H4-Index of npj Vaccines is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Assessing immunogenicity barriers of the HIV-1 envelope trimer	192
Reverse development of vaccines against antimicrobial-resistant pathogens	133
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine	114
Analyzing atomic force microscopy images of virus-like particles by expectation-maximization	114
Risk assessment of retinal vascular occlusion after COVID-19 vaccination	111
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants	104
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year	93
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice	93
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity	92
Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection	80
The dengue-specific immune response and antibody identification with machine learning	77
Immunogenicity and safety of a rabies-based highly pathogenic influenza A virus H5 vaccine in cattle	73
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern	65
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys	62
Influenza A virus in dairy cattle: infection biology and potential mammary gland-targeted vaccines	62
A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle	59
Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine	59
Rational development of a combined mRNA vaccine against COVID-19 and influenza	58
Mapping global public perspectives on mRNA vaccines and therapeutics	58
Immune response against SARS-CoV-2 variants: the role of neutralization assays	57
PfRH5 vaccine; from the bench to the vial	57
Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development	57
LmCen−/− based vaccine is protective against canine visceral leishmaniasis following three natural exposures in Tunisia	57
Protein engineering strategies for rational immunogen design	57
Author Correction: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax	55

A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens	54
Genome-wide association study of myocarditis and pericarditis following COVID-19 vaccination	53
Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox	52
A field test of empathetic refutational and motivational interviewing to address vaccine hesitancy among patients	50
SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition	49
Single-dose intranasal adenovirus-based RSV vaccines targeting G and M2	49
Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen	46
Use of equine H3N8 hemagglutinin as a broadly protective influenza vaccine immunogen	46
Immune response induced by standard and fractional doses of 17DD yellow fever vaccine	46
Leishmania tarentolae as a platform for the production of vaccines against viral pathogens	45
GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus	45
Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex	45
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth	44
IL-12 mRNA-LNP promotes dermal resident memory CD4+ T cell development	43
Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates	43
Antibody responses against influenza A decline with successive years of annual influenza vaccination	41
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants	41
Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice	41